|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, January 03, 2018 ) The North America Diabetic Retinopathy Market has been estimated at USD 2.14 billion in 2016 and is projected to reach USD 2.86 billion by 2021, at a CAGR of 6.05% during the forecast period from 2016 to 2021. North America leads the global diabetic retinopathy market due to huge number of aging population. North America market is geographically segmented into USA and Canada.
View Full Report @ https://www.marketdataforecast.com/market-reports/north-america-diabetic-retinopathy-market-937/
Diabetic retinopathy is a result of long term diabetes that affects eyes. It's triggered by destruction of the blood vessels of the light-sensitive tissue at the back of the eye (retina). At first, diabetic retinopathy may show no symptoms or only slight vision difficulties. Eventually, it can cause blindness.
Request Sample @ https://www.marketdataforecast.com/market-reports/north-america-diabetic-retinopathy-market-937/request-sample
Increasing management financial support, rising occurrence of diabetics, alteration in lifestyle and global elderly population are the factors driving the market growth. However, dearth of accurate diagnosis and prolonged approval time for drugs are hindering the growth of global diabetic retinopathy market. Increasing healthcare awareness is also powering the growth of global diabetic retinopathy market.
Inquire Before Buy @ https://www.marketdataforecast.com/market-reports/north-america-diabetic-retinopathy-market-937/inquire
The North America Diabetic Retinopathy Market has been segmented on the basis of indication into Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR). NPDR is further sub segmented as Mild, Moderate and Severe. Based on Treatment type the market is bifurcated into Anti-Vascular Endothelial Growth Factor (VEGF) drug, Intraocular Steroid Injection, Laser Surgery and Vitrectomy. By end users division is among Hospitals, Ophthalmic Clinics and Ambulatory Surgical Centers. Non-proliferative retinopathy dominated the overall market size estimated to lead the market. Augmented incidence of diabetes, lack of diagnosis at right time, and non-compliant retinal screening of diabetic patients are projected to propel the growth of non-proliferative diabetic retinopathy market share.
Buy Now @ https://www.marketdataforecast.com/cart/buy-now/north-america-diabetic-retinopathy-market-937
The Major companies in Diabetic Retinopathy treatment market are Bayer AG, Pfizer Inc., Hoffmann-La Roche ltd, Regeneron Pharmaceutical Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc. and Ampio Pharmaceuticals Inc.
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: abhishek@marketdataforecast.com
Market Data Forecast
Abhishek
+1-888- 702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
